Phase 2 Multiple Myeloma, Refractory Clinical Trials
6 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc127 enrolled16 locationsNCT04414475
Recruiting
Phase 2
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University27 enrolled1 locationNCT06822972
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 2
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Polina Stepensky180 enrolled1 locationNCT06971380
Recruiting
Phase 2
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University25 enrolled1 locationNCT06158412
Recruiting
Phase 2
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics39 enrolled2 locationsNCT06115135